⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Summit Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Summit Therapeutics
↗Boston, USA
Summit Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-friendly medicinal therapies to resolve serious unmet medical needs. Originally founded as a UK-based biotechnology company (Summit plc) with a focus on antibiotic innovation and drug discovery platforms, the company has evolved into an oncology-focused organization.
The company is currently heavily invested in the development of ivonescimab, a novel bispecific antibody, through strategic partnerships. It maintains a global presence with operations in the United States and the United Kingdom, continuing its mission to improve patient outcomes through precision therapeutic healthcare solutions.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2003
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ
Ticker:SMMT
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Bispecific antibody, Small molecule
Trial Phases:Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Akeso, Inc. (Licensing and collaboration for ivonescimab)
COMPETITION
Position:Emerging
Competitors:Merck & Co., AstraZeneca, Roche
LEADERSHIP
Key Executives:
Robert W. Duggan - CEO
LINKS
Website:summitplc.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Summit Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.